Clinical Trials

Delafloxacin—a novel broad spectrum fluoroquinolone intended for use as an effective and convenient first-line therapy primarily in hospitals prior to the availability of a specific diagnosis.

Upcoming clinical trials

• Phase 3 trial (the first of two planned Phase 3 trials) for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA to begin in 2H 2012

 

Completed clinical trials

• Phase 2b trial for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including infections caused by MRSA
• Phase 2 trial for the treatment of complicated skin and skin structure infections (cSSSI)
• Phase 2 trial for the treatment of bronchitis
• Phase 2 trial for the treatment of community acquired pneumonia (CAP)
• 16 Phase 1 trials

Radezolid—a next-generation, IV/oral oxazolidinone designed to meet the need for a potent antibiotic with a safety profile permitting long-term treatment of resistant infections, including MRSA.

Completed clinical trials

• Phase 1 study to evaluate intravenous formulation
• Phase 2 trial for the treatment of community acquired pneumonia (CAP)
• Phase 2 trial for the treatment of uncomplicated skin and skin structure infections (uSSSI)